Carvedilol administration in acute myocardial infarction results in stronger inhibition of early markers of left ventricular remodeling than metoprolol

International Journal of Cardiology

Volumn 153, Issue 3, 2011, Pages 256-261

  Cimmino, Giovanni ^a,c   Ibanez, Borja ^a,b,d   Giannarelli, Chiara ^a   Prat González, Susanna ^a   Hutter, Randolph ^a   Garcia, Mario ^a   Sanz, Javier ^a   Fuster, Valentin ^a,b   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Adrenergic receptors; Heart failure; Ischemia reperfusion; Myocardial infarction; Remodelling

Indexed keywords

CARVEDILOL; GELATINASE A; METOPROLOL; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; DISEASE MARKER; DRUG ACTIVITY; LEFT VENTRICULAR REMODELING; MACROPHAGE MIGRATION INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANIMALS; BIOLOGICAL MARKERS; CARBAZOLES; DOWN-REGULATION; METOPROLOL; MYOCARDIAL INFARCTION; PROPANOLAMINES; RANDOM ALLOCATION; SWINE; VENTRICULAR REMODELING;

EID: 81855190682     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2010.08.018     Document Type: Article

References (26)

1. E.M. Antman, M. Hand, and P.W. Armstrong 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee Circulation 117 2008 296 329
2. P.A. Poole-Wilson, K. Swedberg, and J.G. Cleland Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial Lancet 362 2003 7 13 (Pubitemid 36835815)
3. R. Tolg, M. Witt, and B. Schwarz Comparison of carvedilol and metoprolol in patients with acute myocardial infarction undergoing primary coronary intervention - the PASSAT Study Clin Res Cardiol 95 2006 31 41 (Pubitemid 43155313)
4. O. Dewald, P. Zymek, and K. Winkelmann CCL2/Monocyte Chemoattractant Protein-1 regulates inflammatory responses critical to healing myocardial infarcts Circ Res 96 2005 881 889 (Pubitemid 40604972)
5. M.R. Bergman, J.R. Teerlink, and R. Mahimkar Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction Am J Physiol Heart Circ Physiol 292 2007 H1847 H1860
6. E.F. Lewis, L.A. Moye, and J.L. Rouleau Predictors of late development of heart failure in stable survivors of myocardial infarction: the CARE study J Am Coll Cardiol 42 2003 1446 1453 (Pubitemid 37267288)
7. S.C. Wolf, G. Sauter, J. Jobst, V.A. Kempf, T. Risler, and B.R. Brehm Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment Int J Cardiol 125 2008 4 10 (Pubitemid 351305421)
8. T.C. Wu, Y.H. Chen, and H.B. Leu Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis Free Radic Biol Med 43 2007 1508 1522
9. C. Liang, L. Xiaonan, and C. Xiaojun Effect of metoprolol on vulnerable plaque in rabbits by changing shear stress around plaque and reducing inflammation Eur J Pharmacol 613 2009 79 85
10. B. Ibanez, S. Prat-Gonzalez, and W.S. Speidl Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance Circulation 115 2007 2909 2916 (Pubitemid 46915384)
11. B. Ibanez, G. Cimmino, and S. Prat-Gonzalez The cardioprotection granted by metoprolol is restricted to its administration prior to coronary reperfusion Int J Cardiol 2009
12. R. Roberts, W.J. Rogers, and H.S. Mueller Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study Circulation 83 1991 422 437
13. S. Basu, R. Senior, U. Raval, R. van der Does, T. Bruckner, and A. Lahiri Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial Circulation 96 1997 183 191 (Pubitemid 27298420)
14. W.G. Arsenault, D.M. Boothe, S.G. Gordon, M.W. Miller, J.R. Chalkley, and I. Petrikovics Pharmacokinetics of carvedilol after intravenous and oral administration in conscious healthy dogs Am J Vet Res 66 2005 2172 2176
15. J. Rugtveit, H. Scott, T.S. Halstensen, J. Norstein, and P. Brandtzaeg Expression of the L1 antigen (calprotectin) by tissue macrophages reflects recent recruitment from peripheral blood rather than upregulation of local synthesis: implications for rejection diagnosis in formalin-fixed kidney specimens J Pathol 180 1996 194 199 (Pubitemid 26370187)
16. H. Morimoto, M. Takahashi, and A. Izawa Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction Circ Res 99 2006 891 899 (Pubitemid 44556389)
17. O. Dewald, N.G. Frangogiannis, and M. Zoerlein Development of murine ischemic cardiomyopathy is associated with a transient inflammatory reaction and depends on reactive oxygen species Proc Natl Acad Sci U S A 100 2003 2700 2705 (Pubitemid 36297562)
18. M. Kobara, N. Sunagawa, and M. Abe Apoptotic myocytes generate monocyte chemoattractant protein-1 and mediate macrophage recruitment J Appl Physiol 104 2008 601 609 (Pubitemid 351468786)
19. S. Hayashidani, H. Tsutsui, and T. Shiomi Anti-monocyte chemoattractant protein-1 gene therapy attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 108 2003 2134 2140 (Pubitemid 37337591)
20. K. Kaikita, T. Hayasaki, T. Okuma, W.A. Kuziel, H. Ogawa, and M. Takeya Targeted deletion of CC chemokine receptor 2 attenuates left ventricular remodeling after experimental myocardial infarction Am J Pathol 165 2004 439 447 (Pubitemid 38971374)
21. N.G. Frangogiannis, O. Dewald, and Y. Xia Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy Circulation 115 2007 584 592 (Pubitemid 46226168)
22. Y. Maekawa, T. Anzai, and T. Yoshikawa Effect of granulocyte-macrophage colony-stimulating factor inducer on left ventricular remodeling after acute myocardial infarction J Am Coll Cardiol 44 2004 1510 1520 (Pubitemid 39303957)
23. S.C. Tyagi, S.G. Kumar, J. Banks, and W. Fortson Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium J Mol Cell Cardiol 27 1995 2177 2189
24. S. Matsumura, S. Iwanaga, S. Mochizuki, H. Okamoto, S. Ogawa, and Y. Okada Targeted deletion or pharmacological inhibition of MMP-2 prevents cardiac rupture after myocardial infarction in mice J Clin Invest 115 2005 599 609 (Pubitemid 40322234)
25. J.T. Peterson, H. Li, L. Dillon, and J.W. Bryant Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat Cardiovasc Res 46 2000 307 315 (Pubitemid 30204603)
26. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150